Berotralstat - BioCryst Pharmaceuticals
Alternative Names: PrORLADEYO; BCX-7353; Berotralstatum; ORLADEYOLatest Information Update: 12 Aug 2024
At a glance
- Originator BioCryst Pharmaceuticals
- Developer BioCryst Pharmaceuticals; Pint Pharma
- Class Amides; Fluorinated hydrocarbons; Pyrazoles; Skin disorder therapies; Small molecules; Vascular disorder therapies
- Mechanism of Action Kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hereditary angioedema
Most Recent Events
- 05 Aug 2024 BioCryst Pharmaceuticals plans to submit a regulatory filing for Berotralstat for the treatment of Hereditary Angioedema (In children) in 2025 (PO, Granules)
- 09 Jul 2024 Registered for Hereditary angioedema (In adults, In adolescents, In the elderly, Prevention) in Peru (PO)
- 13 May 2024 Registered for Hereditary angioedema (In adolescents, In adults, In the elderly, Prevention) in Mexico (PO)